86770-69-6

Usage

Uses

Used in Bioconjugation:
Azido-PEG6 is used as a bioconjugation agent for the attachment of biomolecules to other molecules or surfaces. The azide group facilitates the formation of stable triazole linkages through Click Chemistry, enabling the efficient and specific binding of biomolecules.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Azido-PEG6 is used as a component in drug delivery systems to improve the solubility, stability, and bioavailability of drugs. The hydroxyl group allows for the attachment of drug molecules or other functional groups, enhancing the overall performance of the drug delivery system.
Used in Materials Science:
Azido-PEG6 is utilized as a building block in the synthesis of functional polymers and materials. The azide group can be used to create cross-links or incorporate other reactive groups, while the hydroxyl group provides opportunities for further modification or attachment of specific functional groups, contributing to the development of advanced materials with tailored properties.
Used in Chemical Synthesis:
In chemical synthesis, Azido-PEG6 serves as an intermediate or reactant for the preparation of various compounds. The azide and hydroxyl groups offer multiple points of reactivity, allowing for the synthesis of a wide range of products with diverse applications.

Upstream product

• 669556-37-0 17-(tetrahydro-2H-pyran-2-yloxy)-3,6,9,12,15-pentaoxaheptadecyl 4-methylbenzenesulfonate 
• 352439-34-0 17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl methanesulfonate 
• 42749-28-0 toluene-4-sulfonic acid 2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl ester 
• 86520-52-7 2-[2-(2-azidoethoxy)ethoxy]ethanol 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 39160-70-8 3,6,9,12,15,18-hexaoxa-1-octadecyl amine 
• 139115-90-5 2-(2-azidoethoxy)ethanol 
• 77544-68-4 8-tosyloxy-3,6-dioxaoctanol 
• 69502-33-6 2-(2-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate 
• 136399-07-0 17-iodo-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 28746-78-3 17-chloro-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 2615-15-8 pentaethylene glycol 
• 98-59-9 p-toluenesulfonyl chloride 
• 1352550-66-3 17-azido-3,6,9,12,15-pentaoxaheptadecyl 2-chloroacetate 

Downstream Products

• 39160-70-8 3,6,9,12,15,18-hexaoxa-1-octadecyl amine 
• 297162-49-3 tert-butyl 20-azido-3,6,9,12,15,18-hexaoxaeicosanoate 
• 129449-09-8 29-amino-3,6,9,12,15,18,21,24,27-nonaoxanonacosan-1-ol 
• 877239-08-2 1-azide-31,31,31-triphenyl-3,6,9,12,15,18,21,24,27,30-decaoxahentriacontanol 
• 1402411-90-8 17-azido-1-bromo-3,6,9,12,15-pentaoxaheptadecane 
• 1196449-89-4 ARM-H 
• 1293397-11-1 C₃₄H₄₃BrN₆O₁₀ 
• 1432887-55-2 C₄₇H₅₉BF₂N₆O₇ 
• 1432887-71-2 C₅₆H₆₄BF₂N₇O₇ 
• 1448451-77-1 C₃₅H₄₄N₄O₁₃ 
• 1448451-72-6 tert-butyl 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-oate 
• 1104083-46-6 20-amino-3,6,9,12,15,18-hexaoxaicosanoic acid 
• 1448451-78-2 C₂₉H₄₄N₄O₁₂ 
• 1448451-79-3 C₃₁H₄₅F₃N₂O₁₃ 

Relevant academic research and scientific papers

THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM

The present application is directed to a therapeutically useful compound, comprised of two monomers that are linked to each other through two or more reversible covalent bonds. Each monomer is a polyfunctionalized molecule comprising a bioorthogonal linker element and ligand or pharmacophore, wherein the linker and ligand/pharmacophore are covalently coupled to each other either directly or through an optional connector moiety.

THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE

The present application is directed to a therapeutic composition, comprising two precursor compounds (monomers) that are suitable for assembly via two or more reversible covalent bonds. The monomers are polyfunctionalized molecules comprising a bioorthogo

Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase

PI3K kinase plays an important role in regulating key processes in cells, such as cell growth, metabolism, proliferation, and apoptosis. The overexpression of PI3K kinase exists in many cancers. The proteolytic target chimera (PROTAC) technology is a new technology that uses the ubiquitin–proteasome system to degrade a given target protein. It has been described that CRBN-based PROTAC targets the degradation of PI3K kinase. However, PROTAC based on VHL has not been reported yet. Here, we connected the previously obtained highly active PI3K inhibitor to the VHL ligand through different small molecules, and obtained a series of PROTAC molecules targeting PI3K kinase. Obtain the most active compound through screening. It provides evidence for the feasibility of PROTAC technology to recruit VHL E3 ligase in PI3K kinase.

COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION

The invention relates to activated Michael acceptor (AMA) compounds that can undergo conjugation with biomolecules containing Michael donor moieties, thereby providing plasma-stable antibody-drug conjugates (ADCs). Pharmaceutical compositions of the ADCs are disclosed as well. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Supramolecular compound nano-carrier as well as preparation method and application thereof

The invention discloses a supramolecular compound nano-carrier as well as a preparation method and application thereof, and relates to the technical field of polymer chemistry and biological detection engineering. According to the supramolecular compound nano-carrier disclosed by the invention, a two-dimensional nanosheet supramolecular structure system generated by self-assembly is driven by an anion induction effect, and a supramolecular compound nano-carrier is of a single-layer nanosheet supramolecular structure constructed by a highly-oriented one-dimensional nanorod. A hydrophobic perylene group part is used as a skeleton part for constructing the highly-oriented one-dimensional nanorod, and the charge density of a single-layer nanosheet can be regulated and controlled. The surface of the water-soluble multivalent hydrophilic part can be loaded with DNAzyme deoxyribozyme for specific detection of heavy metal ions through electrostatic interaction, and the water-soluble multivalent supramolecular compound nano sensor is constructed. Based on a fluorescence change mechanism caused by specific cutting of heavy metal ions, The fluorescence detection of the heavy metal ions in food and biological tissues is realized, and the detection effect of the heavy metal ions is greatly enhanced.

ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

PROTAC compound for targeted degradation of IDO1, and preparation method and application thereof

The invention provides a PROTAC compound represented by formula I and used for targeted degradation of IDO1, and a pharmaceutically acceptable salt, a hydrate or a solvate thereof. In the formula I, Xrepresents -CH2 or -C = O, Y represents -CH2 or -C= O, and n is a natural number from 2 to 9. The PROTAC compound for targeted degradation of the IDO1 has efficient activity of targeted degradation of the IDO1 protein.

Synthesis of branched monodisperse oligoethylene glycols and 19f mri-traceable biomaterials through reductive dimerization of azides

Multifunctionalized and branched M-OEGs represent valuable PEGylation agents, linkers, and scaffolds in biomedicine. However, the tedious synthesis limited their availability and application. We herein present an azide reductive dimerization method for the convenient synthesis of aza-M-OEGs and derivatives, which provides easy access to a variety of multifunctionalized and branched M-OEGs in one step. With this method, hexa-arm M-OEGs with 54 symmetrical fluorines were synthesized in two steps as a water-soluble, self-assemble, 19F MRI sensitive, and biocompatible dendritic biomaterial.

A synthetic 2,3-diarylindole induces microtubule destabilization and G2/M cell cycle arrest in lung cancer cells

The anticancer potential of a synthetic 2,3-diarylindole (PCNT13) has been demonstrated in A549 lung cancer cells by inducing both apoptosis and autophagic cell death. In this report, we designed to connect a fluorophore to the compound via a hydrophilic linker for monitoring intracellular localization. The best position for linker attachment was identified from cytotoxicity and effect on cell morphology of newly synthesized PCNT13 derivatives bearing hydrophilic linker. Cytotoxicity and effect on cell morphology related to the parental compound were used to identify the optimum position for linker attachment in the PCNT13 chemical structure. The fluorophore-PCNT13 conjugate was found to localize in the cytoplasm. Microtubules were found to be one of the cytosolic target proteins of PCNT13, as the compound could inhibit tubulin polymerization in vitro. A molecular docking study revealed that PCNT13 binds at the colchicine binding site on the α/β-tubulin heterodimer. The effect of PCNT13 on microtubule dynamics caused cell cycle arrest in the G2/M phase as analyzed by flow cytometric analysis.

Targeting G Protein-Coupled Receptors with Magnetic Carbon Nanotubes: The Case of the A3 Adenosine Receptor

The A3 adenosine receptor (AR) is a G protein-coupled receptor (GPCR) overexpressed in the membrane of specific cancer cells. Thus, the development of nanosystems targeting this receptor could be a strategy to both treat and diagnose cancer. Iron-filled carbon nanotubes (CNTs) are an optimal platform for theranostic purposes, and the use of a magnetic field can be exploited for cancer magnetic cell sorting and thermal therapy. In this work, we have conjugated an A3AR ligand on the surface of iron-filled CNTs with the aim of targeting cells overexpressing A3ARs. In particular, two conjugates bearing PEG linkers of different length were designed. A docking analysis of A3AR showed that neither CNT nor linker interferes with ligand binding to the receptor; this was confirmed by in vitro preliminary radioligand competition assays on A3AR. Encouraged by this result, magnetic cell sorting was applied to a mixture of cells overexpressing or not the A3AR in which our compound displayed indiscriminate binding to all cells. Despite this, it is the first time that a GPCR ligand has been anchored to a magnetic nanosystem, thus it opens the door to new applications for cancer treatment.